CRISPR Therapeutics AG (CRSP)
| Market Cap | 8.08B |
| Revenue (ttm) | 1.10M |
| Net Income (ttm) | -392.30M |
| Shares Out | 75.77M |
| EPS (ttm) | -5.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $106.64 |
| Previous Close | $101.00 |
| Change ($) | 5.64 |
| Change (%) | 5.58% |
| Day's Open | 101.87 |
| Day's Range | 101.82 - 108.42 |
| Day's Volume | 1,424,732 |
| 52-Week Range | 58.02 - 220.20 |
Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...
One company is setting itself apart in a crowded field.
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)-
The Nasdaq gained ground to start the week.
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the Europe...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...
- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
And they all have one key thing in common.
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
Old crystal balls for viewing fiscal discipline never foresaw this golden age of tech innovation and ultra-low inflation.
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
Last month, we talked about why investors may want to wait for better levels to enter into the CRSP stock. Since then, the stock has seen a correction of over 28%.
CRISPR Therapeutics AG (CRSP) closed at $114.60 in the latest trading session, marking a -0.82% move from the prior day.
These companies may represent the future, but their stocks are getting pummeled in the present.
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $131.10, marking a +0.41% move from the previous day.
It's a firm maybe.
Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.
Tesla's great, but these Cathie Wood favorites have even better growth prospects.
With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...
Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount. The post Why CRSP Stock Is a Less Dicey Risk Asset Today appea...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $114.65, marking a -0.73% move from the previous day.
Yields are on the rise and valuation-propelled tech is getting deflated.
One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.
The companies with game-changing technology are often the best growth picks.
These stocks made investors a lot of money in 2020. Which one will be the better choice this year?
A few months back we talked about why the rally in CRSP stock may continue given the positive developments around CTX001, an experimental gene therapy for people with sickle cell disease and transfusion...
Investors have done great in ARKK, but buying these three ARK Innovation stocks with hedged strategies is today's smart money trade. The post 3 ARK Innovation Stocks to Buy Right Now appeared first on I...
We are glad to announce that we have added Catherine Wood (Trades, Portfolio)'s ARK Investment Management as one of our Premium Gurus.
CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.
- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -
Want to play it safe in a volatile market? Go for these three top-notch healthcare picks.
Bear of the Day: CRISPR Therapeutics (CRSP)
CRISPR Therapeutics AG (CRSP) closed at $168.81 in the latest trading session, marking a +0.61% move from the prior day.
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate... [Read more...]
| Industry Biotechnology | IPO Date Oct 19, 2016 |
| CEO Samarth Kulkarni | Employees 410 |
| Stock Exchange NASDAQ | Ticker Symbol CRSP |
Analyst Forecasts
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 160.18, which is an increase of 50.21% from the latest price.